WPC
CUE icon

Wedmont Private Capital’s Cue Biopharma CUE Stock Holding History

Wedmont Private Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,333
Closed -$76K – 649
2024
Q1 		$76K Buy
1,333
+666
+100% +$47K 0.01% 597
2023
Q4 		$57.2K Hold
667
– – ﹤0.01% 561
2023
Q3 		$40.8K Buy
+667
New +$65.1K ﹤0.01% 501

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Wedmont Private Capital's CUE Position: Q2 2024 in Review

Wedmont Private Capital sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 1,333 shares — an estimated $76K sold.

Wedmont Private Capital first reported a position in CUE in Q3 2023 and held it in 3 quarters. The position peaked at $76K in Q1 2024. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Wedmont Private Capital reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Wedmont Private Capital sold 1,333 Cue Biopharma shares in Q2 2024, an estimated $76K.
  • Wedmont Private Capital first reported a position in Cue Biopharma in Q3 2023 and held it in 3 quarters.
  • Wedmont Private Capital's Cue Biopharma position peaked at $76K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Wedmont Private Capital's 13F filing for Q2 2024, filed 15 Jul 2024.